Literature DB >> 28292436

The Microenvironmental Landscape of Brain Tumors.

Daniela F Quail1, Johanna A Joyce2.   

Abstract

The brain tumor microenvironment (TME) is emerging as a critical regulator of cancer progression in primary and metastatic brain malignancies. The unique properties of this organ require a specific framework for designing TME-targeted interventions. Here, we discuss a number of these distinct features, including brain-resident cell types, the blood-brain barrier, and various aspects of the immune-suppressive environment. We also highlight recent advances in therapeutically targeting the brain TME in cancer. By developing a comprehensive understanding of the complex and interconnected microenvironmental landscape of brain malignancies we will greatly expand the range of therapeutic strategies available to target these deadly diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  blood-brain barrier; brain metastasis; brain tumor microenvironment; glioma; immunotherapy; tumor-associated macrophage

Mesh：

Year:  2017        PMID： 28292436      PMCID： PMC5424263          DOI： 10.1016/j.ccell.2017.02.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  179 in total

Review 1.  Metastatic stem cells: sources, niches, and vital pathways.

Authors:  Thordur Oskarsson; Eduard Batlle; Joan Massagué
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

2.  Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth.

Authors:  Alexander Pietras; Amanda M Katz; Elin J Ekström; Boyoung Wee; John J Halliday; Kenneth L Pitter; Jillian L Werbeck; Nduka M Amankulor; Jason T Huse; Eric C Holland
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

Review 3.  Immunological effects of chemotherapy and radiotherapy against brain tumors.

Authors:  Tobias Weiss; Michael Weller; Patrick Roth
Journal:  Expert Rev Anticancer Ther       Date:  2016-09-06       Impact factor: 4.512

4.  Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels.

Authors:  Qingtang Lin; Krishnakumar Balasubramanian; Dominic Fan; Sun-Jin Kim; Lixia Guo; Hua Wang; Menashe Bar-Eli; Kenneth D Aldape; Isaiah J Fidler
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

Review 5.  S100 proteins in cancer.

Authors:  Anne R Bresnick; David J Weber; Danna B Zimmer
Journal:  Nat Rev Cancer       Date:  2015-02       Impact factor: 60.716

6.  Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.

Authors:  Tai-Gyu Kim; Chang-Hyun Kim; Jung-Sun Park; Sung-Dong Park; Chung Kwon Kim; Dong-Sup Chung; Yong-Kil Hong
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

7.  Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

Authors:  Y Komohara; K Ohnishi; J Kuratsu; M Takeya
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

Authors:  Michele De Palma; Mary Anna Venneri; Rossella Galli; Lucia Sergi Sergi; Letterio S Politi; Maurilio Sampaolesi; Luigi Naldini
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

10.  HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Authors:  James F Curtin; Naiyou Liu; Marianela Candolfi; Weidong Xiong; Hikmat Assi; Kader Yagiz; Matthew R Edwards; Kathrin S Michelsen; Kurt M Kroeger; Chunyan Liu; A K M Ghulam Muhammad; Mary C Clark; Moshe Arditi; Begonya Comin-Anduix; Antoni Ribas; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069
View more
  461 in total

1.  CEREBRAL ORGANOIDS AS A MODEL FOR GLIOBLASTOMA MULTIFORME.

Authors:  Nathaniel Silvia; Guohao Dai
Journal:  Curr Opin Biomed Eng       Date:  2020-03-25

2.  Blockade of CD73 delays glioblastoma growth by modulating the immune environment.

Authors:  J H Azambuja; R S Schuh; L R Michels; I C Iser; L R Beckenkamp; G G Roliano; G S Lenz; J N Scholl; J Sévigny; M R Wink; M A Stefani; A M O Battastini; F Figueiró; H F Teixeira; E Braganhol
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

Review 3.  Updates on Management of Adult Medulloblastoma.

Authors:  Nazanin Majd; Marta Penas-Prado
Journal:  Curr Treat Options Oncol       Date:  2019-06-24

4.  Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages.

Authors:  Zhihong Chen; James L Ross; Dolores Hambardzumyan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

Review 5.  Controversial roles for dexamethasone in glioblastoma - Opportunities for novel vascular targeting therapies.

Authors:  Daniel Dubinski; Elke Hattingen; Christian Senft; Volker Seifert; Kevin G Peters; Yvonne Reiss; Kavi Devraj; Karl H Plate
Journal:  J Cereb Blood Flow Metab       Date:  2019-06-25       Impact factor: 6.200

6.  Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma.

Authors:  Chen Zhu; Cunyi Zou; Gefei Guan; Qing Guo; Zihao Yan; Tianqi Liu; Shuai Shen; Xiaoyan Xu; Chen Chen; Zhiguo Lin; Wen Cheng; Anhua Wu
Journal:  Oncoimmunology       Date:  2019-06-12       Impact factor: 8.110

7.  Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity.

Authors:  Katarzyna C Pituch; Markella Zannikou; Liliana Ilut; Ting Xiao; Michael Chastkofsky; Madina Sukhanova; Nicola Bertolino; Daniele Procissi; Christina Amidei; Craig M Horbinski; Karen S Aboody; C David James; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

8.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

9.  Modelling glioma invasion using 3D bioprinting and scaffold-free 3D culture.

Authors:  Derek M van Pel; Kaori Harada; Dandan Song; Christian C Naus; Wun Chey Sin
Journal:  J Cell Commun Signal       Date:  2018-06-16       Impact factor: 5.782

10.  Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.

Authors:  Yuyu He; Jie Li; Tomoyuki Koga; Jun Ma; Sanjay Dhawan; Yuta Suzuki; Frank Furnari; Varun V Prabhu; Joshua E Allen; Clark C Chen
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.